Novel Coronavirus (SARS-CoV-2/COVID-19)
Children and adolescents in Mississippi who tested positive for the SARS-CoV-2 virus were more likely to report close contact with someone with confirmed COVID-19 and less likely to report consistent mask use at school, according to a study released by the Centers for Disease Control and Prevention…
The AHA released a new edition of the COVID-19 Snapshot, highlighting the critical needs of hospitals and health systems during the deepening public health emergency.
The Food and Drug Administration issued an emergency use authorization for the first over-the-counter fully at-home diagnostic test for COVID-19. The antigen test for persons age 2 and older can detect the SARS-CoV-2 virus in a nasal swab sample in about 20 minutes.
In an open letter, the AHA, American Medical Association and American Nurses Association thanked health care professionals for their dedication and sacrifices this year and urged them to continue their battle against COVID-19 by taking a vaccine and sharing their experience with others.
Ahead of a Dec. 17 meeting of its Vaccines and Related Biological Products Advisory Committee, the Food and Drug Administration released a briefing document confirming Moderna’s data on the safety and efficacy of the mRNA-1273 COVID-19 vaccine candidate.
December 15, 2020
An open letter to all health care professionals:
A bipartisan group of senators and representatives yesterday released legislative text for both the Emergency Coronavirus Relief Act of 2020, a $748 billion COVID-19 relief package that boosts funding for health care providers, vaccines and testing, and the Bipartisan State and Local Support and…
Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published in the New England Journal of Medicine.
The Department of Health and Human Services Dec. 11 announced it would purchase from Moderna 100 million additional doses of its mRNA-1273 COVID-19 vaccine candidate.
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.